Pharmaron Beijing Co's Total Assets for the quarter that ended in Mar. 2024 was ¥25,244 Mil.
Warning Sign:
If a company builds assets at 39.6% a year, faster than its revenue growth rate of 26.7% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Pharmaron Beijing Co's average Total Assets Growth Rate was 8.30% per year.
During the past 3 years, the average Total Assets Growth Rate was 35.30% per year.
During the past 5 years, the average Total Assets Growth Rate was 39.60% per year.
During the past 10 years, Pharmaron Beijing Co's highest 3-Year average Total Assets Growth Rate was 60.30%. The lowest was 30.60%. And the median was 43.70%.
The historical data trend for Pharmaron Beijing Co's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Pharmaron Beijing Co's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmaron Beijing Co (SZSE:300759) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Pharmaron Beijing Co's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Pharmaron Beijing Co Total Assets Related Terms
Thank you for viewing the detailed overview of Pharmaron Beijing Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Pharmaron Beijing Co (SZSE:300759) Business Description
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. The company generates maximum revenue from Laboratory services segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SZSE:300759 has been successfully added to your 